BioInvent International

BioInvent announces first patient enrolled in Phase 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanoma bioinvent.com/en/press/bioin…

BioInvent International AB: Interim report January–September 2024 is out. Read the report: bioinvent.com/en/press/bioin…

Many overlook the importance of toxicity. Martin Welschof, CEO of BioInvent says: Toxicity is as crucial as efficacy. You can’t use what kills you.' A reminder that safety is at least as important as effectiveness in treatments. @BioInvent $BINV is one of the presenting companies at our 15th annual Healthcare Conference today. For all our BioInvent research, access our research and online trading platform (for clients): paretosec.com/updates/events…

From Stockholm: @bioinvent's CEO highlights TNFR2 data recently presented at #ESMO24, and more in the company's pipeline. Full video: biotechtv.com/post/bioinvent…

Busy days #ESMO2024 - European Society for Medical Oncology 2024 - in Barcelona. Today, the BioInvent team presents a Trial in Progress poster for the company’s second anti-TNFR2 antibody, BI-1910. Read the full poster: bioinvent.com/en/our-science…

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments bioinvent.com/en/press/bioin…

BioInvent announces the enrollment of the first patient in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of non-Hodgkin's lymphoma bioinvent.com/en/press/bioin…

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program bioinvent.com/en/press/bioin…

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024 bioinvent.com/en/press/bioin…

BioInvent International Interim Report January-June 2024 released today: bioinvent.com/en/node/1266

BioInvent receives Notice of Allowance from USPTO for BI-1910 patent application Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancer. bioinvent.com/en/press/bioin…

BioInvent to Present Pipeline Progress at ESMO in September 2024. Two posters to be presented on early clinical projects from BioInvent’s robust pipeline totaling six clinical programs. - Progress Phase 1 update for BI-1910 - Initial Phase 1 clinical data for BT-001

BioInvent announces new clinical trial collaboration and supply agreement with MSD to evaluate BI-1607 in combination with KEYTRUDA (pembrolizumab) and ipilimumab. Read more: bioinvent.com/en/press/bioin…

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of anti-TNFR2 agent BI-1808 at PAGE 2024 bioinvent.com/en/press/bioin…

BioInvent gains patent for BI-1808 in China. The patent provides composition-of matter protection for BI-1808 and the use of the antibody for the treatment of cancer. bioinvent.com/en/press/bioin…

Did you miss our KOL event yesterday? No worries, watch it here, anytime: lifescievents.com/event/bioinven… The event features Alexander Eggermont, MD, PhD (University Medical Center Utrecht), on the topic "Where are we going next with immuno-oncology?" and CEO, CMO and CSO.

Today is the Day - don't miss out! Our KOL event starts at 3 pm CEST/9 am EDT. Registration details below.

BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent’s lead candidates BI-1808 and BI-1206 and TNFR2 and FcyRIIB are promising targets in immuno-oncology. To register, visit: lifescievents.com/event/bioinvent

BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 and Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024. bioinvent.com/en

BioInvent presents additional promising Phase 1/2a data at EHA 2024 for BI-1206 with rituximab in NHL. Read the press release: bioinvent.com/en/press/bioin…